Sagimet a new buy at Guggenheim on promise of MASH, acne asset
Source: SeekingAlpha
2026-02-03 10:57:08 ET
More on Sagimet Biosciences
- Sagimet's Denifanstat: China Phase III Safety Data Isn't A Negative Signal
- Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market
- Sagimet Biosciences Advances Denifanstat: Q3 Earnings And Upcoming Catalysts
- Sagimet down as Chinese partner posts late-stage trial data for acne therapy
- Sagimet rises as licensing deal with Teva unit targets Madrigal drug
Read the full article on Seeking Alpha
For further details see:
Sagimet a new buy at Guggenheim on promise of MASH, acne asset
Sagimet Biosciences Inc.
NASDAQ: SGMT
SGMT Trading
-4.08% G/L:
$5.17 Last:
208,102 Volume:
$5.41 Open:
SGMT Latest News
March 11, 2026 07:30:00 am
Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
February 05, 2026 07:00:00 am
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
SGMT Stock Data
$183,421,818
25,724,585
0.29%
25
N/A
Biotechnology & Life Sciences
Healthcare
US
San Mateo
